STREM-1 predicts intensive care unit and 28-day mortality in cancer patients with severe sepsis and septic shock

Journal of Critical Care

Volumn 30, Issue 2, 2015, Pages 440.e7-440.e13

  Ravetti, Cecilia Gómez ^a,b   Moura, Anselmo Dornas ^b   Vieira, Érica Leandro ^a   Pedroso, Enio Roberto Pietra ^a   Teixeira, Antônio Lúcio ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b Hospital Mater Dei   (Brazil)

Author keywords

Cancer; Cytokines sTREM 1; HMGB 1; Intensive care unit; Septic shock; Severe sepsis

Indexed keywords

HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 1; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER; CYTOKINE; HMGB1 PROTEIN, HUMAN; IMMUNOGLOBULIN RECEPTOR; MEMBRANE PROTEIN; TREM1 PROTEIN, HUMAN;

AGED; AREA UNDER THE CURVE; ARTICLE; ARTIFICIAL VENTILATION; BLOOD SAMPLING; CANCER MORTALITY; CANCER PATIENT; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INNATE IMMUNITY; INTENSIVE CARE; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SEPSIS; SEPTIC SHOCK; BLOOD; CASE CONTROL STUDY; COMPLICATION; INTENSIVE CARE UNIT; MIDDLE AGED; MORTALITY; NEOPLASM; PROGNOSIS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; COHORT STUDIES; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HMGB1 PROTEIN; HUMANS; INTENSIVE CARE UNITS; INTERLEUKIN-10; INTERLEUKIN-6; INTERLEUKIN-8; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTORS, IMMUNOLOGIC; RESPIRATION, ARTIFICIAL; ROC CURVE; SEPSIS; SHOCK, SEPTIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84923080047     PISSN: 08839441     EISSN: 15578615     Source Type: Journal    
DOI: 10.1016/j.jcrc.2014.12.002     Document Type: Article

References (40)

1. Angus D.C., Linde-Zwirble W.T., Lidicker J., Clermont G., Carcillo J., Pinsky M.R. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001, 29:1303-1310.
2. Martin G.S., Mannino D.M., Eaton S., Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003, 348:1546-1554.
3. Dellinger R.P., Levy M.M., Carlet J.M., Bion J., Parker M.M., Jaeschke R., et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 2008, 34:17-60.
4. Danai P.A., Moss M., Mannino D.M., Martin G.S The epidemiology of sepsis in patients with malignancy. Chest 2006, 129:1432-1440.
5. Dhainaut J.F., Claessens Y.E., Janes J., Nelson D.R. Underlying disorders and their impact on the host response to infection. Clin Infect Dis 2005, 41:481-489.
6. Vincent J.L., Sakr Y., Sprung C.L., Ranieri V.M., Reinhart K., Gerlach H., et al. Soap Study. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 2006, 34:344-353.
7. Phua J., Koay E.S.C., Lee K.H. Lactate, procalcitonin, and amino-terminal pro-B-type natriuretic peptide versus cytokine measurements and clinical severity scores for prognostication in septic shock. Shock 2008, 29:328-333.
8. Carrigan S.D., Scott G., Tabrizian M. Toward resolving the challenges of sepsis diagnosis. Clin Chem 2004, 50:1301-1314.
9. Kofoed K., Andersen O., Kronborg G., Tvede M., Peterson J., Eugen-Olsen J., et al. Use of plasma C-reactive protein, procalcitonin, neutrophils, macrophage migration inhibitory factor, soluble urokinase-type plasminogen activator receptor, and soluble triggering receptor expressed on myeloid cells-1 in combination to diagnose infections: a prospective study. Crit Care 2007, 11:38.
10. Sundén-Culberg J., Norrby-Teglund A., Rouhiainen A., Rauvala H., Herman G., Tracey K.J., et al. Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock. Crit Care Med 2005, 33:564-575.
11. Gibot S., Massin F., Cravoisy A., Nace L., Levy B., et al. High mobility group box 1 protein plasma concentrations during septic shock. Intensive Care Med 2007, 33:1347-1353.
12. Gibot S., Kollop-Sarda M.N., Bene M.C., Cravoisy A., Levy B., Faure G.C, et al. Plasma level of a triggering receptor expressed on myeloid cells-1: its diagnostic accuracy in patients with suspected sepsis. Ann Intern Med 2004, 141:9-15.
13. Rivera-Chavez F.A., Minei J.P. Soluble triggering receptor expressed on myeloid cells-1 is an early marker of infection in the surgical intensive care unit. Surg Infect 2009, 10:435-439.
14. Zhang J., She D., Feng D., Jia Y., Xie L. Dynamic changes of serum soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) reflect sepsis severity and can predict prognosis: a prospective study. BMC Infect Dis 2011, 1:11-53.
15. Bopp C., Hofer S., Bouchon A., Zimmermann J.B., Martin E., Weigand M.A. Soluble TREM-1 is not suitable for distinguishing between systemic inflammatory response syndrome and sepsis survivors and nonsurvivors in the early stage of acute inflammation. Eur J Anaesthesiol 2009, 26:504-507.
16. Phua J., Koay E.S., Zhang D., Lee K.H. How well do serum sTREM-1 measurements prognosticate in septic shock?. Anaesth Intensive Care 2008, 36:654-658.
17. Kwofie L., Rapoport B.L., Fickl H., Meyer P.W., Rheeder P., Hlope H., et al. Evaluation of circulating soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) to predict risk profile, response to antimicrobial therapy, and development of complications in patients with chemotherapy-associated febrile neutropenia: a pilot study. Ann Hematol 2012, 91:605-611.
18. Soares M., Caruso P., Silva E., Teles J.M., Lobo S.M., Friedman J., et al. Characteristics and outcomes of patients with cancer requiring admission to intensive care units: a prospective multicenter study. Crit Care Med 2010, 38:9-15.
19. Kress J.P., Christenson J., Pohlman A.S., Linkin D.R., Hall J.B. Outcomes of critically ill cancer patients in a university hospital setting. Am J Respir Crit Care Med 1999, 160:1957-1961.
20. Azoulay E., Moreau D., Alberti C., Leleu G., Adrie C., Barboteu M., et al. Predictors of short-term mortality in critically ill patients with solid malignancies. Intensive Care Med 2000, 26:1817-1823.
21. Souza-Dantas V.C., Salluh J.I., Soares M. Impact of neutropenia on the outcomes of critically ill patients with cancer: a matched case-control study. Ann Oncol 2011, 22:2094-2100.
22. American College Of Chest Physicians/Society Of Critical Care Medicine Consensus Conference, 1991, Chicago. Chest 1992, 101:1644-1655.
23. Taccone F.S., Artigas A.A., Sprung C.L., Moreno R., Sakr Y., Vincent J.L. Characteristics and outcomes of cancer patients in European ICUs. Curr Opin Oncol 2009, 21:318-326.
24. Pène F., Percheron S., Lemiale V., Viallon V., Claessens Y.E., Marqué S., et al. Temporal changes in management and outcome of septic shock in patients with malignancies in the intensive care unit. Crit Care Med 2008, 36:690-696.
25. Williams M.D., Braun L.A., Cooper L.M., Johnston J., Weiss R.V, Qualy R.L, et al. Hospitalized cancer patients with severe sepsis: analysis of incidence, mortality, and associated costs of care. Crit Care 2004, 8:R291-R298.
26. Namendys-Silva S.A., Gonzalez-Herrera M.O., Txcocano-Becerra J., Herrera-Gómez A. Clinical characteristics and outcomes of critically ill cancer patients with septic shock. Q J Med 2011, 104:505-511.
27. Staudinger T., Stoiser B., Mullner M., Locker G.J, Lackzika K., Knapp S., et al. Outcome and prognostic factors in critically ill cancer patients admitted to the intensive care unit. Crit Care Med 2000, 28:1322-1328.
28. Regazzoni C.J., Irrazabal C., Luna C.M., Poderoso J.J Cancer patients with septic shock: mortality predictors and neutropenia. Support Care Cancer 2004, 12:833-839.
29. Rosolem M.M., Rabello L.S.C.F., Lisboa T., Caruso P., Costa R.T, Leal J.V, et al. Critical ill patients with cancer and sepsis: clinical course and prognostic factors. J Crit Care 2011, 27:301-307.
30. Larché J., Azoulay E., Fieux F., Mesnard L., Moreau D., Thiery G., et al. Improved survival of critically ill cancer patients with septic shock. Intensive Care Med 2003, 29:1688-1695.
31. Thiery G., Azoulay E., Darmon M., Ciroldi M., De Miranda S., Lèvy V., et al. Outcome of cancer patients considered for intensive care unit admission: a hospital-wide prospective study. J Clin Oncol 2005, 23:4406-4413.
32. Groeger J.S., White P., Nierman D.M., Glassman J., Shi W., Horak D., et al. Outcome for cancer patients requiring mechanical ventilation. J Clin Oncol 1999, 17:991-997.
33. Soares M., Salluh J.I.F., Spector N., Torelli A.P, Silva E., Rezende E., et al. Characteristics and outcomes of cancer patients requiring mechanical ventilatory support for > 24 h. Crit Care Med 2005, 33:520-526.
34. Regazzoni C.J., Khoury M., Irrazabal C., Myburg C., Galvalisi N.R, Flaherty M.OD Neutropenia and the development of the systemic inflammatory response syndrome. Intensive Care Med 2003, 29:135-138.
35. Póvoa P., Souza-Dantas V.C., Soares M., Salluh J.F C-reactive protein in critically ill cancer patients with sepsis: influence of neutropenia. Crit Care 2011, 15:R129.
36. Gibot S., le renard P.E., Bollaert P.E., Kolopp-Sarda M.N, Béné M.C, Faure G.C, et al. Surface triggering receptor expressed on myeloid cells 1 expression patterns in septic shock. Intensive Care Med 2005, 31:594-597.
37. Giamarellos-Bourboulis E.J., Zakynthinos S., Baziaka F., Papadomichelakis E., Virtzili S., Koutoukas P., et al. Soluble triggering receptor expressed on myeloid cells 1 as an anti-inflammatory mediator in sepsis. Intensive Care Med 2006, 32:237-243.
38. Jeong S.J., Song Y.G., Kim C.O., Kim H.W, Ku N.S, Han S.H, et al. Measurement of plasma sTREM-1 in patients with severe sepsis receiving early goal-directed therapy and evaluation of its usefulness. Shock 2012, 37:574-578.
39. Vincent J.L., Moreno R., Takala J., Willatts S., De Mendonça A., Bruining H., et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Int Care Med 1996, 22:707-710.
40. Knaus W.A., Draper E.A., Wagner D.P., Zimmerman J.E. APACHE II: a severity of disease classification system. Crit Care Med 1985, 13:818-829.